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Summary:
There is an increased mortality associated with adrenal insufficiency despite glucocorticoid 
replacement therapy with a standardised mortality ratio greater than two. The cause of the increased 
mortality is yet to be definitively elucidated, but may be due to excess steroid exposure, or 
replacement regimens that are uncoupled from the normal physiological cortisol profile. Cortisol 
secretion follows an ultradian pattern which is not possible to reproduce using oral replacement. With 
the advent of new pumps, it is now possible to mimic the pulsatility of the adrenal glands. Whilst the 
cognitive and emotional benefits of reproducing the ultradian rhythm is known, the presence of long-
term benefits are not yet clear.
There is a dearth of evidence and high-quality studies to underline our current understanding of the 
pathophysiology of adrenal insufficiency and replacement therapy. There is a particular lack of 
research comparing objective outcomes between patients receiving hydrocortisone replacement 
(either standard therapy or new sustained release preparations), prednisolone replacement, and 
ultradian pumps. Direct comparative studies are now warranted to understand the optimal approach.
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There is no doubt that steroid replacement with glucocorticoids saves lives in patients with adrenal 
insufficiency, a condition with an associated mortality of 100% before the development of 
glucocorticoids1. Excess glucocorticoid exposure, as evidenced by patients with Cushing’s syndrome, 
can also be fatal. Remarkably however, there is no agreement on how we can optimise replacement 
therapy for either primary or secondary adrenal insufficiency. Several options result in excess 
glucocorticoid exposure, which may reduce the risk of an Addisonian crisis, but only at the cost of a 
reduced natural killer cell function2, an increased cardiovascular disease burden3,4, and increased 
mortality5. Whether the increased mortality is the result of excessive exposure to glucocorticoid, or 
inappropriate timing and rhythm of replacement remains unclear.
The importance of circadian rhythmicity has been clear for a long time and life forms from primitive 
cyanobacteria, through all phyla to man, have adapted to this with mechanisms to predict the 
changing environments of the 24-hour day. Uncoupling glucocorticoid dose timing from the normal 
circadian cortisol rhythm is harmful6,7 and human cells have developed circadian clocks that are, to 
varying extents, kept in synchrony by the HPA axis 8. Cortisol levels rise at around 4am, under the 
influence of the central circadian pacemaker in the hypothalamic suprachiasmatic nucleus. This 
activates or inhibits a massive variety of genes in all tissues of the body, in anticipation of the body’s 
needs at awakening and can also alter the endogenous clock gene “setting” of cells 9. Misalignment 
between cortisol levels and clock time is one of the factors contributing to the adverse health 
outcomes seen in shift workers and problems associated with jet lag 10.
Oral preparations of glucocorticoids
The excess replacement that frequently occurs with twice or thrice daily hydrocortisone is associated 
with an increase in cardiovascular deaths in these patients, especially with escalating doses 4 and the 
late peaks in cortisol might be harmful 11. A delayed release preparation (Chronocort) taken last thing 
at night 12 has the theoretical advantage of mimicking the early morning 4am rise in cortisol, which 
cannot be achieved with other preparations. Chronocort has already shown potential to suppress 
morning and 24-hour androsteinedione  levels in patients with congenital adrenal hyperplasia during 
phase II trials13, but more studies are needed to determine the clinical importance of this anticipatory 
rise in cortisol. 
Another strategy available in some countries is the use of dual release hydrocortisone (Plenadren) 
once daily first thing in the morning. This sustained release preparation fails to replicate the pre-
awakening rise in cortisol and we know very little about what happens to blood or tissue levels of 
cortisol overnight. It relies on continuous absorption of hydrocortisone from the gut which can be 
variable, a problem that must be guarded against in patients with infectious diarrhoea, when 
glucocorticoids are crucial 14. The manufacturers state that Plenadren is commonly associated (> 1 in 
10 cases) with gastrointestinal side effects 15.
Building on the early comparative findings that Plenadren may lower blood pressure, weight and 
improve HbA1c compared to multiple daily cortisone acetate or hydrocortisone16, the DREAM study 
undertook a similar comparison17. Although the primary outcome focussed on weight change, the 
DREAM study also looked at the effect of Plenadren on immune profiles. Recruiting 89 patients on 
multiple daily cortisone acetate or hydrocortisone, the investigators switched 46 patients to 






























































Plenadren and asked 43 to continue on the thrice daily immediate release preparations. A third group 
of 25 healthy volunteers were also recruited and data collected over a 24-week follow up period. In 
addition to a significant corrected weight loss of 4Kg in the switch group, the investigators reported 
significantly higher classical (CD14+CD16-) monocytes, with lower non-classical (CD14-CD16+) 
monocytes and CD16+ mature natural killer cells in patients taking thrice-daily hydrocortisone at 
baseline versus the healthy volunteers. Converting patients  to once daily Plenadren was associated 
with improved numbers of the classical and non-classical monocytes and the  mature natural killer 
cells, with concordant decreases in the soluble CD16 immune marker (an indicator of natural killer cell 
immaturity) and reported rates of infection as measured by a questionnaire17. These finding suggest 
that Plenadren may be less immunosuppressive than multiple daily dosing of glucocorticoids and that 
leucocytes may hold the key to assessing the adequacy of an individual’s glucocorticoid replacement 
therapy. Because a majority of the patients were on cortisone acetate, it is not clear whether the 
variable metabolism of cortisone to cortisol might be a factor. 
A DREAM ancillary study also investigated the effect of the switch to Plenadren on the RNA expression 
of clock genes. The analysis found that 19 of 68 different clock genes were differently expressed at 
baseline in all patients taking thrice daily hydrocortisone compared to the healthy volunteer control 
group18. In the switch group, the expression of 18 of the 19 affected genes were found to normalised 
to the levels seen within the healthy volunteers over 12 weeks. Clock genes are involved in auto-
regulated feedback cycles thought to be responsible for conveying clock time to individual tissues and 
cells. The oscillations of clock genes regulate and control the transcription of proteins and can inform 
tissue sensitivity to glucocorticoids depending on the time of day, through acetylation of lysine 
residues on the glucocorticoid receptor6,19.  Although dissociation of peripheral clock genes and the 
central suprachiasmatic clock is associated with disease states, the functional significance is not 
understood19. The physiological improvements demonstrated by Plenadren have been attributed to 
its ability to better mirror the natural circadian cortisol profile, compared to multiple daily 
hydrocortisone or cortisone acetate although this association might simply be due to the lower steroid 
exposure seen with Plenadren, with data indicating a reduction of approximately 20% in area-under-
the curve exposure16.A majority of the patients were on cortisone acetate, which depends on hepatic 
activation by 11β hydroxysteroid dehydrogenase (11βHSD1) to cortisol20. It was assumed that 1mg of 
cortisone acetate was equivalent to 0.8mg of hydrocortisone17  but, there is a large (21% to 95%) 
variability in bioavailability of cortisone acetate21 as well as tissue specific expression of 11βHSD1.
Prednisolone22 has a similar plasma profile to Plenadren and since this is taken on wakening, the 4am 
anticipatory rise in glucocorticoid does not occur. At a molecular level we know that prednisolone has 
prolonged binding to the glucocorticoid receptor compared to hydrocortisone, which would be 
expected to result in different transcriptional responses in glucocorticoid responsive tissues and 
prolonged effect 23. Whether this theoretical advantage is clinically useful and results in reduced risk 
of adrenal crisis is unknown. The rate of adrenal crises has grown with the increased prescription of 
short-acting glucocorticoids such as hydrocortisone, although a causal link needs to be confirmed24. 
Further data from a prospective observational study in Germany recorded the frequency of crises 
experienced by patients on different treatment regimens, and showed that the proportion of patients 
on prednisolone experiencing a crisis was not greater than expected25. It is however clear that 
previously used doses have been excessive and 3mg to 4mg once daily is sufficient replacement in 
most patients 26,27. Currently there are two NIHR adopted studies actively recruiting, comparing low-
dose prednisolone with standard regimens of hydrocortisone28,29. Low dose prednisolone has been 
shown to be superior in reducing androgens, 17-hydroxy progesterone and improving growth velocity 
in patients with congenital adrenal hyperplasia compared to thrice daily hydrocortisone 30.   































































Infusion pumps have been used to mimic the circadian rise in morning cortisol. In addition to 
normalising morning ACTH levels in patients with primary adrenal failure, improvements in physical 
functioning and vitality domains of the SF-36 have been noted 31,32. There are however no further 
anthropometric or objective benefits, and in double-blind placebo-controlled conditions when 
compared to oral hydrocortisone treatment, the subjective health outcome benefits are no longer 
detectable 33.  These studies were performed without any pulsatile or ultradian patterns. 
Like many other hormones cortisol is secreted in a pulsatile manner 34,35. This results in a circadian 
rhythm that is made up of underlying oscillations which reach maximum amplitude at the time of the 
circadian peak. In animal models these pulses have been shown to be very important for normal 
physiological and behavioural activity36,37. Although there is relatively little variation of circadian 
rhythm between subjects, there is much more intra-individual variation in the daily pattern of 
ultradian pulses34.  Since the frequency of ultradian pulses simply depends on fixed delays in the 
feedforward-feedback relationship between the pituitary corticotropes and the adrenal fasciculata 
cells38,39 the circadian change in cortisol is determined by changes in pulse amplitude rather than pulse 
frequency. This provides us with a much easier opportunity to use pumps to replicate physiological 
pulses, as demonstrated by Russell and colleagues40. 
It is not yet clear to what extent it is important to replicate these rhythms to provide optimal 
treatment for patients with adrenal failure. Although we know that stress increases the size of 
ultradian pulses 41,42, there have been no long term studies on the modulation of ultradian rhythmicity 
in normal daily living. Physiological studies have shown that it is the presence of both peaks and 
troughs of cortisol that is important for optimal regulation of behaviour and of glucocorticoid and 
mineralocorticoid receptors in animals 43,44. We are now testing this in new psychological paradigms 
in man.
From a patient’s perspective infusion pumps are less convenient than tablets. However, the 
technological advances of new miniature nanopumps either external or with subcutaneous reservoirs 
will make pumps less intrusive. Kalafatakis and colleagues recently undertook a double-blind 
randomised crossover study, in which they recruited 15 young males and implemented a “block and 
replace” approach to cortisol using three distinct regimens to investigate the comparative effects of 
pulsatility on cognition, emotion and sleep 45. Participants had their endogenous cortisol secretion 
blocked using metyrapone and received 20mg of hydrocortisone in three modalities: 1- a 
subcutaneous pulsatile mode to replicate the ultradian profile; 2- a subcutaneous cutaneous infusion; 
3- oral thrice daily replacement, each for a five-day period. The order in which the modalities were 
administered was randomised.
The study demonstrated that pulsatility directly affects neurological physiology in the non-stressed 
state, independent of the cumulative glucocorticoid exposure. Specifically, subcutaneous ultradian 
pulsatile infusions promoted better quality of sleep and improved performance of working memory 
compared to the continuous infusions, as assessed by a sleep questionnaire and functional tests 
respectively. 
These different patterns of cortisol oscillations also had differential effects on the fMRI and functional 
connectivity of the brain regions which process emotional responses (amygdala, dorsal striatum, 
insula and orbitofrontal cortex) – with parallel changes detected in attentional bias to, and recognition 
accuracy of emotional cues45.






























































These data imply that oscillating levels of cortisol are important for physiological regulation of 
glucocorticoid receptors and post receptor signalling in the brain and for the regulation of mood in 
man. Whether differences in endogenous patterns of pulsatility in different individuals alters these 
functions is unknown. The importance of these pulses in longer term replacement therapy in patients 
with Addison’s disease will be clearer once the Medical Research Council PULSES trial is complete 
(MR/R010919/1).
Neither immediate release hydrocortisone nor any other oral glucocorticoid will ever replace normal 
ultradian secretion which remains highly variable across individuals.  
Conclusion
Long term patient health and cognitive and emotional state as well as patient convenience and 
compliance are crucial and a balance between a once daily oral dosing, more frequent oral dosing and 
the requirement of a pump needs to be considered. Currently there are no good studies comparing 
low dose prednisolone, dual release hydrocortisone (Plenadren, Duocort), delayed release 
hydrocortisone (Chronocort) and miniature ultradian pumps with three times daily hydrocortisone, 
using currently understood lowe  and biologically equivalent doses. We hope that well controlled, 
relatively long-term double-blind studies will soon be available to allow a rational approach to optimal 
therapy on an individual patient basis. 
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Summary:
There is an increased mortality associated with adrenal insufficiency despite glucocorticoid 
replacement therapy with a standardised mortality ratio greater than two. The cause of the increased 
mortality is yet to be definitively elucidated, but may be due to excess steroid exposure, or 
replacement regimens that are uncoupled from the normal physiological cortisol profile. Cortisol 
secretion follows an ultradian pattern which is not possible to reproduce using oral replacement. With 
the advent of new pumps, it is now possible to mimic the pulsatility of the adrenal glands. Whilst the 
cognitive and emotional benefits of reproducing the ultradian rhythm is known, the presence of long-
term benefits are not yet clear.
There is a dearth of evidence and high-quality studies to underline our current understanding of the 
pathophysiology of adrenal insufficiency and replacement therapy. There is a particular lack of 
research comparing objective outcomes between patients receiving hydrocortisone replacement 
(either standard therapy or new sustained release preparations), prednisolone replacement, and 
ultradian pumps. Direct comparative studies are now warranted to understand the optimal approach.
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There is no doubt that steroid replacement with glucocorticoids saves lives in patients with adrenal 
insufficiency, a condition with an associated mortality of 100% before the development of 
glucocorticoids1. Excess glucocorticoid exposure, as evidenced by patients with Cushing’s syndrome, 
can also be fatal. Remarkably however, there is no agreement on how we can optimise replacement 
therapy for either primary or secondary adrenal insufficiency. Several options result in excess 
glucocorticoid exposure, which may reduce the risk of an Addisonian crisis, but only at the cost of a 
reduced natural killer cell function2, an increased cardiovascular disease burden3,4, and increased 
mortality5. Whether the increased mortality is the result of excessive exposure to glucocorticoid, or 
inappropriate timing and rhythm of replacement remains unclear.
The importance of circadian rhythmicity has been clear for a long time and life forms from primitive 
cyanobacteria, through all phyla to man, have adapted to this with mechanisms to predict the 
changing environments of the 24-hour day. Uncoupling glucocorticoid dose timing from the normal 
circadian cortisol rhythm is harmful6,7 and human cells have developed circadian clocks that are, to 
varying extents, kept in synchrony by the HPA axis 8. Cortisol levels rise at around 4am, under the 
influence of the central circadian pacemaker in the hypothalamic suprachiasmatic nucleus. This 
activates or inhibits a massive variety of genes in all tissues of the body, in anticipation of the body’s 
needs at awakening and can also alter the endogenous clock gene “setting” of cells 9. Misalignment 
between cortisol levels and clock time is one of the factors contributing to the adverse health 
outcomes seen in shift workers and problems associated with jet lag 10.
Oral preparations of glucocorticoids
The excess replacement that frequently occurs with twice or thrice daily hydrocortisone is associated 
with an increase in cardiovascular deaths in these patients, especially with escalating doses 4 and the 
late peaks in cortisol might be harmful 11. A delayed release preparation (Chronocort) taken last thing 
at night 12 has the theoretical advantage of mimicking the early morning 4am rise in cortisol, which 
cannot be achieved with other preparations. Chronocort has already shown potential to suppress 
morning and 24-hour androsteinedione  levels in patients with congenital adrenal hyperplasia during 
phase II trials13, but more studies are needed to determine the clinical importance of this anticipatory 
rise in cortisol. Unfortunately in the most recent trials, Chronocort was unable to achieve its primary 
outcome of showing superiority over standard care in congenital adrenal hyperplasia during phase III 
trials, and further development on it is currently on hold.
Another strategy available in some countries is the use of dual release hydrocortisone (Plenadren) 
once daily first thing in the morning. This sustained release preparation fails to replicate the pre-
awakening rise in cortisol and we know very little about what happens to blood or tissue levels of 
cortisol overnight. It relies on continuous absorption of hydrocortisone from the gut which can be 
variable, a problem that must be guarded against in patients with infectious diarrhoea, when 
glucocorticoids are crucial 14. The manufacturers state that Plenadren is commonly associated (> 1 in 
10 cases) with gastrointestinal side effects 15.
Building on the early comparative findings that Plenadren may lower blood pressure, weight and 
improve HbA1c compared to multiple daily cortisone acetate or hydrocortisone16, the DREAM study 
undertook a similar comparison17. Although the primary outcome focussed on weight change, the 






























































DREAM study also looked at the effect of Plenadren on immune profiles. Recruiting 89 patients on 
multiple daily cortisone acetate or hydrocortisone, the investigators switched 46 patients to 
Plenadren and asked 43 to continue on the thrice daily immediate release preparations. A third group 
of 25 healthy volunteers were also recruited and data collected over a 24-week follow up period. In 
addition to a significant corrected weight loss of 4Kg in the switch group, the investigators reported 
significantly higher classical (CD14+CD16-) monocytes, with lower non-classical (CD14-CD16+) 
monocytes and CD16+ mature natural killer cells in patients taking thrice-daily hydrocortisone at 
baseline versus the healthy volunteers. Converting patients  to once daily Plenadren was associated 
with improved numbers of the classical and non-classical monocytes and the  mature natural killer 
cells, with concordant decreases in the soluble CD16 immune marker (an indicator of natural killer cell 
immaturity) and reported rates of infection as measured by a questionnaire17. These finding suggest 
that Plenadren may be less immunosuppressive than multiple daily dosing of glucocorticoids and that 
leucocytes may hold the key to assessing the adequacy of an individual’s glucocorticoid replacement 
therapy. Because a majority of the patients were on cortisone acetate, it is not clear whether the 
variable metabolism of cortisone to cortisol might be a factor. 
A DREAM ancillary study also investigated the effect of the switch to Plenadren on the RNA expression 
of clock genes. The analysis found that 19 of 68 different clock genes were differently expressed at 
baseline in all patients taking thrice daily hydrocortisone compared to the healthy volunteer control 
group18. In the switch group, the expression of 18 of the 19 affected genes were found to normalised 
to the levels seen within the healthy volunteers over 12 weeks. Clock genes are involved in auto-
regulated feedback cycles thought to be responsible for conveying clock time to individual tissues and 
cells. The oscillations of clock genes regulate and control the transcription of proteins and can inform 
tissue sensitivity to glucocorticoids depending on the time of day, through acetylation of lysine 
residues on the glucocorticoid receptor6,19.  Although dissociation of peripheral clock genes and the 
central suprachiasmatic clock is associated with disease states, the functional significance is not 
understood19. The physiological improvements demonstrated by Plenadren have been attributed to 
its ability to better mirror the natural circadian cortisol profile, compared to multiple daily 
hydrocortisone or cortisone acetate although this association might simply be due to the lower steroid 
exposure seen with Plenadren, with data indicating a reduction of approximately 20% in area-under-
the curve exposure16.A majority of the patients were on cortisone acetate, which depends on hepatic 
activation by 11β hydroxysteroid dehydrogenase (11βHSD1) to cortisol20. It was assumed that 1mg of 
cortisone acetate was equivalent to 0.8mg of hydrocortisone17  but, there is a large (21% to 95%) 
variability in bioavailability of cortisone acetate21 as well as tissue specific expression of 11βHSD1.
Prednisolone22 has a similar plasma profile to Plenadren and since this is taken on wakening, the 4am 
anticipatory rise in glucocorticoid does not occur. At a molecular level we know that prednisolone has 
prolonged binding to the glucocorticoid receptor compared to hydrocortisone, which would be 
expected to result in different transcriptional responses in glucocorticoid responsive tissues and 
prolonged effect 23. Whether this theoretical advantage is clinically useful and results in reduced risk 
of adrenal crisis is unknown. The rate of adrenal crises has grown with the increased prescription of 
short-acting glucocorticoids such as hydrocortisone, although a causal link needs to be confirmed24. 
Further data from a prospective observational study in Germany recorded the frequency of crises 
experienced by patients on different treatment regimens, and showed that the proportion of patients 
on prednisolone experiencing a crisis was not greater than expected25. It is however clear that 
previously used doses have been excessive and 3mg to 4mg once daily is sufficient replacement in 
most patients 26,27. Currently there are two NIHR adopted studies actively recruiting, comparing low-
dose prednisolone with standard regimens of hydrocortisone28,29. Low dose prednisolone has been 






























































shown to be superior in reducing androgens, 17-hydroxy progesterone and improving growth velocity 
in patients with congenital adrenal hyperplasia compared to thrice daily hydrocortisone 30.   
Subcutaneous glucocorticoid infusions
Infusion pumps have been used to mimic the circadian rise in morning cortisol. In addition to 
normalising morning ACTH levels in patients with primary adrenal failure, improvements in physical 
functioning and vitality domains of the SF-36 have been noted 31,32. There are however no further 
anthropometric or objective benefits, and in double-blind placebo-controlled conditions when 
compared to oral hydrocortisone treatment, the subjective health outcome benefits are no longer 
detectable 33.  These studies were performed without any pulsatile or ultradian patterns. 
Like many other hormones cortisol is secreted in a pulsatile manner 34,35. This results in a circadian 
rhythm that is made up of underlying oscillations which reach maximum amplitude at the time of the 
circadian peak. In animal models these pulses have been shown to be very important for normal 
physiological and behavioural activity36,37. Although there is relatively little variation of circadian 
rhythm between subjects, there is much more intra-individual variation in the daily pattern of 
ultradian pulses34.  Since the frequency of ultradian pulses simply depends on fixed delays in the 
feedforward-feedback relationship between the pituitary corticotropes and the adrenal fasciculata 
cells38,39 the circadian change in cortisol is determined by changes in pulse amplitude rather than pulse 
frequency. This provides us with a much easier opportunity to use pumps to replicate physiological 
pulses, as demonstrated by Russell and colleagues40. 
It is not yet clear to what extent it is impo tant to replicate these rhythms to provide optimal 
treatment for patients with adrenal failure. Although we know that stress increases the size of 
ultradian pulses 41,42, there have been no long term studies on the modulation of ultradian rhythmicity 
in normal daily living. Physiological studies have shown that it is the presence of both peaks and 
troughs of cortisol that is important for optimal regulation of behaviour and of glucocorticoid and 
mineralocorticoid receptors in animals 43,44. We are now testing this in new psychological paradigms 
in man.
From a patient’s perspective infusion pumps are less convenient than tablets. However, the 
technological advances of new miniature nanopumps either external or with subcutaneous reservoirs 
will make pumps less intrusive. Kalafatakis and colleagues recently undertook a double-blind 
randomised crossover study, in which they recruited 15 young males and implemented a “block and 
replace” approach to cortisol using three distinct regimens to investigate the comparative effects of 
pulsatility on cognition, emotion and sleep 45. Participants had their endogenous cortisol secretion 
blocked using metyrapone and received 20mg of hydrocortisone in three modalities: 1- a 
subcutaneous pulsatile mode to replicate the ultradian profile; 2- a subcutaneous cutaneous infusion; 
3- oral thrice daily replacement, each for a five-day period. The order in which the modalities were 
administered was randomised.
The study demonstrated that pulsatility directly affects neurological physiology in the non-stressed 
state, independent of the cumulative glucocorticoid exposure. Specifically, subcutaneous ultradian 
pulsatile infusions promoted better quality of sleep and improved performance of working memory 
compared to the continuous infusions, as assessed by a sleep questionnaire and functional tests 
respectively. 






























































These different patterns of cortisol oscillations also had differential effects on the fMRI and functional 
connectivity of the brain regions which process emotional responses (amygdala, dorsal striatum, 
insula and orbitofrontal cortex) – with parallel changes detected in attentional bias to, and recognition 
accuracy of emotional cues45.
These data imply that oscillating levels of cortisol are important for physiological regulation of 
glucocorticoid receptors and post receptor signalling in the brain and for the regulation of mood in 
man. Whether differences in endogenous patterns of pulsatility in different individuals alters these 
functions is unknown. The importance of these pulses in longer term replacement therapy in patients 
with Addison’s disease will be clearer once the Medical Research Council PULSES trial is complete 
(MR/R010919/1).
Neither immediate release hydrocortisone nor any other oral glucocorticoid will ever replace normal 
ultradian secretion which remains highly variable across individuals.  
Conclusion
Long term patient health and cognitive and emotional state as well as patient convenience and 
compliance are crucial and a balance between a once daily oral dosing, more frequent oral dosing and 
the requirement of a pump needs to be considered. Currently there are no good studies comparing 
low dose prednisolone, dual release hydrocortisone (Plenadren, Duocort), delayed release 
hydrocortisone (Chronocort) and miniature ultradian pumps with three times daily hydrocortisone, 
using currently understood lower and biologically equivalent doses. We hope that well controlled, 
relatively long-term double-blind studies will soon be available to allow a rational approach to optimal 
therapy on an individual patient basis. 
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